Cargando…

Clinical efficacy and bleeding outcomes of tissue plasminogen activator and dornase alfa in pleural space infection with once daily concurrent administration: a retrospective cohort study

OBJECTIVE: The use of intrapleural tissue plasminogen activator (tPA) and dornase alfa (DNase) is common in the management of pleural space infection. We review our experience with the efficacy and safety of this therapy. We performed a single center, retrospective study of consecutive patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Chuan, Xie, Meng, Cervellione, Kelly, Thurm, Craig
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Note
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398294/ https://www.ncbi.nlm.nih.gov/pubmed/32746902 http://dx.doi.org/10.1186/s13104-020-05210-2

Ejemplares similares

Intrapleural Tissue Plasminogen Activator and Dornase Alfa Administration for a Multiloculated Recurrent Malignant Pleural Effusion: A Case Report
por: Nikoomanesh, Kia, et al.
Publicado: (2022)

The use of dornase alfa in patients with COVID-19
por: Ramachandram, Dinesh Sangarran, et al.
Publicado: (2023)

Aerosol Delivery of Dornase Alfa Generated by Jet and Mesh Nebulizers
por: Chang, Kyung Hwa, et al.
Publicado: (2020)

Consideration of dornase alfa for the treatment of severe COVID-19 acute respiratory distress syndrome
por: Earhart, A.P., et al.
Publicado: (2020)

The Use of Dornase Alfa in the Management of COVID-19-Associated Adult Respiratory Distress Syndrome
por: Toma, Andrew, et al.
Publicado: (2021)

Dornase alfa in Cystic Fibrosis: indications, comparative studies and effects on lung clearance index
por: Terlizzi, Vito, et al.
Publicado: (2022)

Preliminary report of in vitro and in vivo effectiveness of dornase alfa on SARS-CoV-2 infection
por: Okur, H.K., et al.
Publicado: (2020)

Non-Randomized Trial of Dornase Alfa for Acute Respiratory Distress Syndrome Secondary to Covid-19
por: Holliday, Zachary M., et al.
Publicado: (2021)

USE OF ALTEPLASE AND DORNASE FOR LYSIS OF COVID-19-RELATED LOCULATED PLEURAL EFFUSION
por: STAIANO, PETER P, et al.
Publicado: (2022)

Use of dornase alfa in the paediatric intensive care unit: current literature and a national cross-sectional survey
por: den Hollander, Bibiche, et al.
Publicado: (2022)

Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: a case series
por: Weber, Andrew G., et al.
Publicado: (2020)

Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: A case series
por: Weber, Andrew G., et al.
Publicado: (2020)

Effect of Dornase Alfa on the Lung Clearance Index in Children with Cystic Fibrosis: A Lesson from a Case Series
por: Terlizzi, Vito, et al.
Publicado: (2022)

Intrapleural Dornase and Tissue Plasminogen Activator in pediatric empyema (DTPA): a study protocol for a randomized controlled trial
por: Livingston, Michael H., et al.
Publicado: (2017)

Rethinking the Doses of Tissue Plasminogen Activator and Deoxyribonuclease Administrated Concurrently for Intrapleural Therapy for Complicated Pleural Effusion and Empyema
por: Innabi, Ayoub, et al.
Publicado: (2018)

A first-year dornase alfa treatment impact on clinical parameters of patients with cystic fibrosis: the Brazilian cystic fibrosis multicenter study
por: Rozov, Tatiana, et al.
Publicado: (2013)

Dornase alpha use in patients with cystic fibrosis
por: Marostica, Paulo José C.
Publicado: (2013)

Effects of Concurrent Dosing on the Efficacy of Tissue Plasminogen Activator and Deoxyribonuclease in the Treatment of Pleural Infection
por: Pathak, Vikas, et al.
Publicado: (2023)

Experience with ceftaroline for treatment of methicillin-resistant Staphylococcus aureus pneumonia in a community hospital
por: Karki, Apurwa, et al.
Publicado: (2017)

Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily Versus Twice-Daily Radiotherapy (CONVERT) Trial
por: Christodoulou, Marianna, et al.
Publicado: (2019)

Nebulised dornase alfa versus placebo or hypertonic saline in adult critically ill patients: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis
por: Claudius, Casper, et al.
Publicado: (2015)

Early glottic cancer treatment with concurrent chemoradiotherapy with once-daily orally administered S-1
por: Takase, Yuuki, et al.
Publicado: (2021)

Efficacy and safety of aerosolized intra-tracheal dornase alfa administration in patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS): a structured summary of a study protocol for a randomised controlled trial
por: Desilles, J. P., et al.
Publicado: (2020)

Protocol for TRAUMADORNASE: a prospective, randomized, multicentre, double-blinded, placebo-controlled clinical trial of aerosolized dornase alfa to reduce the incidence of moderate-to-severe hypoxaemia in ventilated trauma patients
por: Pottecher, Julien, et al.
Publicado: (2020)

Comparison of Once-Daily Administration of Edoxaban and Rivaroxaban in Asian Patients with Atrial Fibrillation
por: Lee, So-Ryoung, et al.
Publicado: (2019)

Once-daily dosing of gentamicin.
por: Soper, D E
Publicado: (1998)

Protocol for the CONVERT trial—Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status
por: Faivre-Finn, Corinne, et al.
Publicado: (2016)

Tacrolimus monotherapy in a patient with lupus flare using once-daily administration protocol
por: Tanaka, Hiroshi, et al.
Publicado: (2011)

Metabolic and Cognitive Outcomes of Subchronic Once-Daily Intranasal Insulin Administration in Healthy Men
por: Ritze, Yvonne, et al.
Publicado: (2018)

Safety and Efficacy of Intrapleural Tissue Plasminogen Activator and DNase during Extended Use in Complicated Pleural Space Infections
por: McClune, Jason R., et al.
Publicado: (2016)

ONCE DAILY RISPERIDONE IN TREATMENT OF SCHIZOPHRENIA
por: Agarwal, Vivek, et al.
Publicado: (2001)

Evaluation of nephrotoxicity and ototoxicity following amikacin administration once daily or every 48 hours in neonates
por: Endo, Aiju, et al.
Publicado: (2022)

Once-Daily Subcutaneous Irisin Administration Mitigates Depression- and Anxiety-like Behavior in Young Mice
por: Pignataro, Patrizia, et al.
Publicado: (2023)

Compliance with Once-Daily versus Twice or Thrice-Daily Administration of Antibiotic Regimens: A Meta-Analysis of Randomized Controlled Trials
por: Falagas, Matthew E., et al.
Publicado: (2015)

Comparison of Once-Daily Bromfenac 0.07% Versus Once-Daily Nepafenac 0.3% in Patients Undergoing Phacoemulsification
por: Toyos, Melissa M.
Publicado: (2019)

Is the Urokinase Plasminogen Activator/Plasminogen Activator Inhibitor-1 Ratio a Marker of Sonographic Septations in Pleural Infection?
por: Yasuma, Taro, et al.
Publicado: (2022)

Benefits of once-daily therapies in the treatment of hypertension
por: Flack, John M, et al.
Publicado: (2011)

ONCE DAILY LITHIUM IN THE PROPHYLAXIS OF MOOD DISORDERS
por: Mohan, Rajesh, et al.
Publicado: (1996)

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin
por: Kapitza, C, et al.
Publicado: (2013)

Administration of follitropin alfa and lutropin alfa combined in a single injection: a feasibility assessment
por: Agostinetto, Rita
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_gdi79chos3v5sfcqis823b1kjh